Identification of Critical Ligand Binding Determinants in *Mycobacterium tuberculosis* Adenosine-5′-phosphosulfate Reductase

Jiyoung A. Hong,[†] Devayani P. Bhave,[‡] and Kate S. Carroll*,[†,‡,§]

[†]*Department of Chemistry,* [‡]*Chemical Biology Graduate Program, and* [§]*Life Sciences Institute, University of Michigan, 210 Washtenaw Avenue, Ann Arbor, Michigan 48109-2216*

Mycobacterium tuberculosis adenosine-5′-phosphosulfate (APS) reductase is an iron−sulfur protein and a validated target to develop new antitubercular agents, particularly for the treatment of latent infection. To facilitate the development of potent and specific inhibitors of APS reductase, we have probed the molecular determinants that underlie binding and specificity through a series of substrate and product analogues. Our study highlights the importance of specific substitutent groups for substrate binding and provides functional evidence for ligand-specific conformational states. An active site model has been developed for *M. tuberculosis* APS reductase that is in accord with the results presented here as well as prior structural data reported for *Pseudomonas aeruginosa* APS reductase and related enzymes. This model illustrates the functional features required for the interaction of APS reductase with a ligand and provides a pharmacological roadmap for the rational design of small molecules as potential inhibitors of APS reductase present in human pathogens, including *M. tuberculosis*.

1. Introduction

Reduced sulfur appears in organic compounds essential to all organisms as constituents of proteins, coenzymes, and cellular metabolites.[1−3] In the amino acid cysteine, the thiol functional group plays important biological roles in redox chemistry, metal binding, protein structure, and catalysis.[4] In many human pathogens such as *Mycobacterium tuberculosis* and *Pseudomonas aeruginosa*, activation of inorganic sulfur for the biosynthesis of cysteine proceeds via adenosine-5′-phosphosulfate (APS[a]).[5,6] This high-energy intermediate is produced by the action of ATP sulfurylase, which condenses sulfate and adenosine-5′-triphosphate (ATP) to form APS.[1] The iron−sulfur protein, APS reductase catalyzes the first committed step in sulfate reduction and is a validated target to develop new antitubercular agents, particularly for the treatment of latent infection.[7−9]

APS reductase catalyzes the reduction of APS to sulfite (SO_3^{2-}) and adenosine-5′-monophosphate (AMP) using reduction potential supplied by the protein cofactor, thioredoxin, as shown in Figure 1. Functional and structural studies have been used to investigate the mechanism of APS reductase from sulfate-assimilating bacteria.[10−12] The proposed mechanism in Figure 2 involves nucleophilic attack by cysteine 256 (Residue numbers throughout manuscript correspond to the APS reductase sequence from *P. aeruginosa* (Figure S1, Supporting Information) on the sulfur atom in APS to form an enzyme *S*-sulfocysteine intermediate, $E\text{-Cys-}S\gamma\text{-}SO_3^{-}$, which is then reduced through intermolecular thiol−disulfide exchange with thioredoxin. The iron−sulfur cluster in APS reductase is essential for activity; however, it is not involved in redox chemistry and its exact role remains unknown.[6,11]

Crystal structure determination at 2.7 Å of *P. aeruginosa* APS reductase in complex with APS provided the first insight into the molecular basis for substrate recognition (Figure 3).[12] *M. tuberculosis* and *P. aeruginosa* APS reductases are related by high sequence homology (27.2% of sequence identity and 41.4% of sequence similarity), particularly in the residues that line the active site. The protein monomer folds as a single domain with a central six-stranded β sheet, interleaved with seven α-helices (Figure 3). Opposite the nucleotide at one end of the active site is the [4Fe−4S] cluster. Three additional elements define the active site: the P-loop (residues 60−66), the LDTG motif (residues 85−88), and the Arg-loop (residues 162−173). APS fits into the active site cavity with the phosphosulfate moiety extending toward the protein surface and 10 residues interact directly, via hydrogen bonding or hydrophobic interactions with the substrate. The C-terminal segment of residues 250−267, which carries the catalytically essential Cys256, is disordered in this structure but would be positioned above the active site cleft.

Not all organisms that assimilate sulfate reduce APS as the source of sulfite. Through divergent evolution, some organisms, such as *Escherichia coli* and *Saccharomyces cerevisiae*, reduce the related metabolite 3′-phosphoadenosine-5′-phosphosulfate (PAPS),[10] which is produced by APS kinase from ATP and APS.[13] PAPS reductases lack the iron−sulfur cofactor but utilize the same two-step mechanism shown in

---

*To whom correspondence should be addressed. Phone: 734-615-2739. Fax: 734-764-1075. E-mail: katesc@umich.edu.

[a] Abbreviations: [4Fe-4S], four iron, four sulfur; TB, tuberculosis; ATP, adenosine-5′-triphosphate; AMP, adenosine-5′-monophosphate; PAPS, 3′-phosphoadenosine-5′-phosphosulfate; PAP, 3′-phosphoadenosine-5′-phosphate; ADP, adenosine-5′-diphosphate; ADPβS, adenosine-5′-*O*-β-thiodiphosphate; ADPβF, adenosine-5′-*O*-β-fluorodiphosphate; AMPCF2P, adenosine-5′-*O*-α,β-difluoromethylenediphosphate; AMPCP, adenosine-5′-*O*-α,β-methylenediphosphate; AMPNP, adenosine-5′-*O*-α,β-imidodiphosphate; AMPPN, adenosine-5′-*O*-β-amidodiphosphate; APSβM, adenosine-5′-*O*-α,β-methylenephosphosulfate; AMPS, adenosine-5′-*O*-thiophosphate; AMPN, adenosine-5′-*O*-amidophosphate.

Figure 1. Sulfate assimilation pathway in *M. tuberculosis*. The majority of sulfate reducing bacteria use APS as their source of sulfite. In this reaction, APS is reduced to sulfite and adenosine-5′-monophosphate (AMP) by APS reductase. Sulfite, in turn, is reduced by later enzymes in this metabolic pathway, forming first sulfide before incorporation into cysteine and, ultimately, to methionine and other essential reduced sulfur-containing biomolecules.


Figure 2. Mechanism of sulfonucleotide reduction.

Figure 2.[10,11] *S. cerevisiae* PAPS reductase, crystallized in the presence of the product, 3′-phosphoadenosine-5′-phosphate (PAP),[14] has a fold similar to APS reductase (1.6 Å rms deviation over 117 residues). In the structure of yeast PAPS reductase, the Arg-loop and C-terminal segment are folded over the active site and this conformation reveals additional enzyme−ligand contacts, which may also form between APS reductase and its substrate, APS.

Even though *M. tuberculosis* has plagued humans for millennia, the antibiotic regime is complex and effective drugs that specifically target latent TB infection are yet to be developed.[15] Novel targets[16,17] and treatment strategies[18,19] are emerging, but new avenues for therapeutic intervention must continue to be explored in order to combat multidrug-resistant strains of TB, which pose a significant threat to global human health.[20] To this end, APS reductase represents an attractive target for therapeutic intervention because it is essential for mycobacterial survival in the latent phase of TB infection[9] and humans do not possess an analogous metabolic pathway. Recently, we have discovered small-molecule inhibitors of APS reductase through virtual ligand screening.[21] However, the development of more specific and potent inhibitors will be greatly aided through knowledge of the functional importance of interactions between the substrate and enzyme at the active site, which have not yet been experimentally addressed.

Herein, we probe binding determinants of the *M. tuberculosis* APS reductase active site using synthetic ligand analogues. These studies define chemical groups that are essential


Figure 3. Structure of *P. aeruginosa* APS reductase in complex with substrate, APS (PDB deposition 2GOY). The C-terminal segment of residues starting at Glu249 carries the catalytically essential Cys256 and is disordered.

for molecular recognition and reveal a network of electrostatic interactions, which play an important role in substrate discrimination. An active site model has been developed for *M. tuberculosis* APS reductase that is in accord with the results presented here as well as prior structural data reported for *P. aeruginosa* APS reductase and related enzymes. This model illustrates the functional features required for the interaction of APS reductase with a ligand and provides a pharmacological roadmap for the rational design of small molecules as potential inhibitors of APS reductase present in human pathogens, including *M. tuberculosis*.

Table 1. Ligand Dissociation Constants for Substrate Fragments with APS Reductase

Ligand	Structure	K_d [μM][c]	$\Delta\Delta G$ [kcal/mol][d]	pKa
APS[a]		0.20	N/A	~2 (O)[e]
AMP		5.4	2.0	6.8 (O)[52]
5'-Phosphoribose		93	5.1	~6.8 (O)[f]
Adenosine		3000	5.8	3.6 (N1), 12.4 (O)[54]
Phosphate		66000	7.7	1.97 (O), 6.82 (O), 12.5 (O)[55]
Ribose		680000	9.1	12.22 (O)[56]
Adenine[b]		$\geq$ 90000	$\geq$ 7.3	4.15 (N1), 9.80 (N9)[56]
Sulfate[b]		$\geq$ 310000	$\geq$ 8.6	-3 (O), 1.89 (O)[57]

[a] The K_d of APS was measured under single turnover conditions, in the absence of thioredoxin, as described in the Experimental Procedures. [b] Due to the limits of solubility or solution ideality the reported values are lower limits. [c] For substrate fragments in this table values of K_i were determined under single turnover conditions from the dependence of the observed rate constant at a given inhibitor concentration under conditions of subsaturating APS, such that K_i is equal to the K_d. Each value reflects the average of at least two independent experiments, and the standard deviation was less than 15% of the value of the mean. Kinetic data were nonlinear-least-squares fit to a model of competitive inhibition. [d] Energetic difference in affinity of APS relative to inhibitor, $\Delta\Delta G = -RT \ln(K_d^{APS}/K_d^{fragment})$. [e] p$K$a estimated from value measured for 2'-deoxy-5'-phosphoribose.[58] [f] pKa estimated from value measured for 3'-phospho-5'-adenosinephosphosulfate.[59]

2. Results and Discussion

The substrate and fragments studied and results obtained in these experiments are summarized in Tables 1−3 and Figures 4−9.

2.1. Substrate Affinity. As a starting point to explore the molecular recognition properties of APS reductase, we determined the K_d value of substrate APS for *M. tuberculosis* APS reductase from the dependence of the observed rate constant for *S*-sulfocysteine formation (Figure S2, Supporting Information), as described in Experimental Procedures. The substrate APS binds to APS reductase with a K_d value of $0.2\,\mu$M (Table 1), which is ~3-fold lower than the value of the reported substrate K_m.[22]

2.2. Affinity of Substrate Fragments. To gain further insight into substrate recognition of *M. tuberculosis* APS reductase, we analyzed the energetic contribution of individual portions of APS to the enzyme-binding interaction. The results obtained in these experiments are summarized in Table 1. The product AMP differs chemically from the natural substrate, APS, by the absence of the sulfate moiety. The loss of sulfate from APS reduced binding to APS reductase about 30-fold (2 kcal/mol), demonstrating that the AMP moiety makes a substantial contribution (7.3 kcal/mol) to the overall binding affinity (9.3 kcal/mol) of APS. Deletion of the adenine or phosphate group from AMP decreased binding to APS reductase by ~170-fold (3.1 kcal/mol) and ~550-fold (3.8 kcal/mol), respectively. Fragments of adenosine, D-ribose and adenine, exhibited weak binding activity toward APS reductase (0.2 and ≤1.5 kcal/mol). The respective free energy of binding to sulfate and phosphate dianions was ≤0.7 and 1.6 kcal/mol. Figure 4 summarizes the binding properties of the substrate, APS, and product, AMP for *M. tuberculosis* APS reductase, as compared with those of the fragments obtained by cutting these ligands at several positions, including the glycosidic bond, and at α- or β-positions within the diester moiety. In all cases, the K_d value of APS or AMP was lower than those of its pieces. However, the free energies (ΔG_{conn}) associated with these connectivity effects for APS reductase are modest (≤2.2 kcal/mol) as compared to values that have been determined for adenosine[23] and cytidine deaminases[24] (~10 kcal/mol).

2.3. Affinity of Substrate Analogues. 2.3.1. β-Nucleotide Substitution. The results above suggest that the β-sulfate group plays a modest role (≤2.0 kcal/mol) in molecular

Table 2. Ligand Dissociation Constants for Substrate Analogues with APS Reductase

Ligand	Structure	K_d [μM][a]	$\Delta\Delta G$ [kcal/mol][b]	pKa
ADPβS		0.15	−0.17	5.2 (O)[60]
ADPαS[c]		0.80	0.83	6.8 (O)[61]
ADPβF		2.5	1.5	N/A
ADP		4.3	1.8	6.4 (O)[61]
AMPCF₂P		13	2.5	~5.7 (O)[d]
AMPCP		27	2.9	8.1 (O)[62]
APSαS[c]		43	3.2	~1.6 (O)[e]
AMPNP		260	4.3	7.7 (O), 8.25 (N)[33]
AMPPN		410	4.6	3.0 (O), 8.15 (N)[f]
APSβM		700	4.9	~3.7 (O)[g]

[a] For substrate analogues in this table, values of K_i were determined under single turnover conditions from the dependence of the observed rate constant at a given inhibitor concentration under conditions of subsaturating APS, such that K_i is equal to the K_d. Each value reflects the average of at least two independent experiments, and the standard deviation was less than 15% of the value of the mean. Kinetic data were nonlinear-least-squares fit to a model of competitive inhibition. *[b]* Energetic difference in affinity of APS relative to inhibitor, $\Delta\Delta G = -RT \ln(K_d^{APS}/K_d^{analogue})$. *[c]* K_d value for the diastereoisomeric mixture of R_p and S_p isomers. *[d]* pKa estimated from value for mono- and difluoro-substituted benzylphosphonic acid.[63] *[e]* pKa estimated from effect of thio-substitution on ADPαS.[61] *[f]* pKa estimated from value measured for phosphoramidic acid.[64] *[g]* pKa estimated from effect of β-methylene-substitution on AMPCP.[62]

recognition of APS. To probe this observation in further detail, we investigated binding affinities for a panel of nucleotide analogues containing systematic modifications at

Table 3. Ligand Dissociation Constants for Product AMP Analogues with APS Reductase

Ligand	Structure	K_d [μM][a]	$\Delta\Delta G$ [kcal/mol][b]	pKa
5'-AMPS		3.3	−0.30	5.3 (O)[60]
5'-AMPN		100		~3.0 (N), ~8.15 (O)[c]
3',5'-ADP		770	3.0	2.49 (O), 8.61 (O)[65]
3'-AMP		3200	3.8	5.92 (O)[52]

[a] For analogues in this table, values of K_i were determined under single turnover conditions from the dependence of the observed rate constant at a given inhibitor concentration under conditions of subsaturating APS, such that K_i is equal to the K_d. Each value reflects the average of at least two independent experiments, and the standard deviation was less than 15% of the value of the mean. Kinetic data were nonlinear-least-squares fit to a model of competitive inhibition. *[b]* Energetic difference in affinity of AMP relative to inhibitor, $\Delta\Delta G = -RT \ln(K_d^{AMP}/K_d^{analogue})$. *[c]* p$K$a estimate from value measured for phosphoramidic acid.[64]

the β-position (Table 2 and Figure 5). A phosphate oxyanion has nearly the same size and shape as a sulfate oxyanion, four atoms arranged tetrahedrally around a sulfur instead of a phosphorus.[25,26] However, the overall charge of these analogues differs because the β-sulfate is monoanionic, whereas the β-phosphate is dianionic. Replacement of the β-sulfate moiety with β-phosphate, as in adenosine-5'-diphosphate (ADP), diminished binding to APS reductase about 20-fold (1.8 kcal/mol). To determine whether this decrease in binding affinity is due to additional negative charge at the β-position of ADP, relative to APS, we examined sulfur (ADPβS), fluorine (ADPβF), or amine (AMPPN) substitution of the β-phosphate nonbridging oxygen atom in ADP (Table 2 and Figure 5). Sulfur substitution is considered to be a good mimic of the phosphate moiety because it is isosteric, pseudoisoelectronic, and has a similar charge distribution and similar net charge at physiological pH.[27,28] Fluorine substitution replaces an ionizable hydroxyl group, thereby mimicking the protonated nucleotide species in net charge at all pH values[29] and, at neutral pH, amine substitution neutralizes the −1 charge at the β-position. Compared to ADP, substitution by sulfur increased binding affinity by 2.0 kcal/mol, fluorine increased binding by less than 2-fold (0.3 kcal/mol), and introduction of the amine group decreased the free energy of binding for APS reductase by 2.8 kcal/mol.

Taken together, the above data suggest that a net charge of −2 correlates with potent enzyme−ligand interactions. The negative charge can be localized entirely to the α-position, as in AMP, or it can be distributed across the

Figure 4. Effects of cutting the substrate, APS, and the product, AMP into fragments on ligand K_d values. The energetic effect that results from connectivity was calculated based on the affinity of the parent ligand "XY", compared with the affinities of its pieces, "X" and "Y": $\Delta G_{conn} = -RT \ln(K_{XY}/K_X K_Y)$, as previously reported.[23]


Figure 5. Electrostatic potential surfaces of substrate, APS, and related nucleotide analogues. Color gradient: red corresponds to most negative and blue corresponds to most positive.

diester, as in ADPβF. The similarity of K_d values for AMP and ADP could reflect different modes of nucleotide binding. For example, the α-phosphate of AMP could occupy the same position as the β-phosphate in ADP, thereby establishing key electrostatic interactions with Lys144, Arg242, and Arg245 (Figure 3). However, an upward shift in the position of AMP would likely weaken important enzyme-binding contacts with the adenine ring and ribose sugar of AMP (Figure 3). An alternative possibility is that the C-terminus and Arg-loop of APS reductase could adopt different conformations, depending on whether ADP or AMP is bound at the active site. In other words, binding energy gained through additional charge–charge interactions between the β-phosphate moiety of ADP, Lys144, Arg242,

and Arg245 could be canceled by a decrease in favorable interactions with residues in the C-terminus and the Arg-loop. Evidence in support for the latter proposal is provided in Section 5 below.

Interestingly, substitution of fluorine by an oxyanion had a marginal effect on binding affinity, whereas thiolate substitution increased binding potency by almost 30-fold. The larger size and polarizability of the sulfur atom could enhance binding affinity by: (i) shortening the distance to residues that directly contact the ligand and/or (ii) enabling additional electrostatic or stacking interactions with APS reductase.[30] Finally, we note that neutralizing the -1 charge of the β-phosphate, as in AMPPN, is clearly unfavorable. This significant energetic penalty likely results from

Figure 6. Free energy of binding for purine and ribose-modified analogues of product, AMP. Numbers represent the energetic effect of a given substitution in kcal/mol, relative to AMP ($\Delta\Delta G = -RT \ \ln(K_d^{analogue}/K_d^{AMP})$). Positive $\Delta\Delta G$'s indicate a penalty for substitution.

repulsive electrostatic interactions between the amine group, which is protonated at physiological pH (Figure 5), and adjacent positively charged residues (Figure 3). In line with this hypothesis, the binding affinity of AMPPN for APS reductase increased at elevated pH (Table S1, Supporting Information).

2.3.2. α−β Bridging Oxygen Substitution. Interactions between the 5′-phosphate and two highly conserved residues, Arg171 and His259, are observed in the structure of *S. cerevisiae* PAPS reductase bound to PAP.[14] However, owing to the mobility of the Arg-loop and C-terminal residues, no direct contacts to the α-phosphate are observed in the structure of APS reductase[12] (Figure 3). To gain insight into the functional importance of these contacts for *M. tuberculosis* APS reductase, we examined the contribution of the α−β bridging oxygen to binding affinity (Table 2). Replacing the Pα−O−Sβ bridging oxygen in APS with a methylene group (Pα−CH₂−Sβ) significantly decreased binding affinity by ∼3500-fold (4.9 kcal/mol). Comparison of ADP with AMPNP (Pα−NH−Pβ), AMPCF₂P (Pα−CF₂−Pβ), and AMPCP (Pα−CH₂−Pβ) shows that imino, difluoromethylene, or methylene substitutions reduced binding potency by approximately 60-fold (2.5 kcal/mol), 3-fold (0.7 kcal/mol), and 6-fold (1.1 kcal/mol), respectively.

The above findings demonstrate that the α−β bridging oxygen does contribute to ligand recognition. Nonetheless, these data pose several questions: Why is the methylene substitution more detrimental for APS binding, relative to the energetic penalty paid for similar modification of ADP? And, why does AMPNP bind more weakly to APS reductase compared to AMPCF₂P? Replacing the bridging oxygen with a methylene group decreases the S/P−X−P bond angle, increases S/P−X bond length, increases the negative charge density on nonbridging oxygens, but makes the phosphate and sulfate groups less acidic.[31,32] It is possible that methylene substitution of ADP is less detrimental to binding because (i) the phosphonate moiety has more torsional freedom, allowing the nucleotide to adopt an alternative favorable binding mode and/or (ii) conformational differences in the C-terminal and Arg-loop segments minimize unfavor-


Figure 7. pH dependence for ADP (A) and AMP (B) binding. The association equilibrium constant, ($K_a = 1/K_d$) is plotted as a function of pH. Values of K_d were determined by inhibition of APS reductase (pH 6.0−9.5). Buffers were as follows: MES (pH 6.0−6.5), BisTris (pH 6.5−7.5), TrisHCl (pH 7.5−9.5), CAPS (pH 9−9.5). See Experimental Section for additional details. (A) The pH dependence for ADP binding. Nonlinear-least-squares fit of the data to a model for a single ionization gave pK_a values of 6.4 ± 0.2. (B) The pH dependence for AMP binding. The dashed line represents the best fit of a model for a single ionization and yields a pK_a of 7.9 ± 0.1.

able contacts to the α−β bridging position of AMPCP. NMR studies show that AMPPNP and PNP exist in solution primarily as the imido tautomers.[33] Thus, the observed decrease in binding affinity could be due to restricted rotation about the Pα−NH−Pβ bonds.

2.3.3. α-Nucleotide Substitution. Next, we examined the effect of sulfur substitution at the α-nonbridging oxygen atom using the analogues, APSαS and ADPαS (Table 2). (In principle, APSαS could be utilized as a substrate by APS reductase. However, under saturating conditions, no evidence for formation of the *S*-sulfocysteine intermediate has been obtained (data not shown). At present, it is not understood why APS reductase does not effectively reduce APSαS. One possible explanation is that the α-sulfur substitution disrupts contact with residues that could be important for stabilizing charge development in the transition state, such as Arg171 and His259.) Comparison of APS and APSαS shows that sulfur substitution for oxygen decreased binding by more than 200-fold (3.2 kcal/mol). However, compared to ADP, the binding potency of ADPαS increased by approximately 5-fold (1 kcal/mol). The larger energetic penalty for α-sulfur substitution of APS could result from ligand-related differences in enzyme conformation, similar to the scenario presented in the subsection above.

2.4. Affinity of Product AMP Analogues. 2.4.1. α-Nucleotide Substitution. To probe the molecular binding determinants of APS reductase at the α-position in greater detail, we


Figure 8. APS reductase interactions with substrate, APS inferred from *P. aeruginosa* APS reductase (PDB deposition 2GOY) and *S. cerevisiae* PAPS reductase (PDB deposition 2OQ2) structures and functional data obtained in the present study. (A) Summary of proposed active site contacts to APS. (B) Summary of proposed active site contacts to APS, plotted in two dimensions. A total of nine protein residues are shown in proximity around the ligand, with hydrogen bonding interactions shown where detected. Hydrogen bonds are draw as dotted lines with arrows denoting the direction of the bond. Interactions from substrate or the residue backbones of the enzyme are distinguished from the interactions with residue side chains by a solid dot at the end of the interaction line. Active site residues between *P. aeruginosa* and *M. tuberculosis* APS reductase are largely conserved, with the exception of residues implicated in hydrophobic interactions (Ser62 to Met67, Ser84 to Phe87, Phe61 to Asn66). The corresponding numbers for residues conserved between *M. tuberculosis* and *P. aeruginosa* APS reductase are: Ser65 (Ser60), Leu88 (Leu85), Lys145 (Lys144), Gly162 (Gly161), Arg171 (Arg171), Arg237 (Arg242), Arg240 (Arg245) Cys249 (Cys256), and His252 (His259). See also Figure S1 of the Supporting Information.

compared the K_d value for the product, AMP, to values measured for related analogues (Table 3). The respective effects of substitution at the α-oxygen by sulfur (AMPS) or amine (AMPN) are −0.3 and +1.8 kcal/mol, compared to AMP. The modest increase in binding energy that results from sulfur modification is similar to the effect observed with ADPαS. The reduction in binding affinity of AMPN also parallels the decrease observed for AMPPN.

In PAPS reductase, residues in the P-loop interact with the 3′-phosphate of PAP.[14,34] However, in APS reductase, the acidic residue, Asp66, interacts with amide groups of the P-loop and thus appears to mimic the interaction of the negatively charged 3′-phosphate group. To investigate the role of the 3′-hydroxyl group in ligand discrimination (see also Section 2.4.2 below), we determined the binding affinity for 3′-AMP, which reverses the position of the 5′-phosphate and 3′-hydroxyl groups (Table 3). Switching the position of the phosphate moiety decreased binding by ∼600-fold (3.8 kcal/mol), indicating that, while the analogue binds poorly, the 3′-phosphate does not impact binding to APS reductase, as compared to adenosine. By contrast, addition of a 3′-phosphate group to AMP, as in PAP, decreased binding affinity by 3.0 kcal/mol. The energetic penalty for 3′-phosphate in PAP, but not 3′-AMP, likely reflects additional binding interactions to the 5′-phosphate, which could decrease conformational freedom and increase unfavorable protein−ligand contacts.

2.4.2. Purine and Ribose Substitution. Next, we analyzed the relative energetic contributions of individual purine and ribose substituents to the enzyme-binding interaction. Owing to the relative difficulties traditionally associated with the preparation of ADP analogues and the weak binding of adenosine, we determined affinities for a series of compounds derived from the AMP scaffold. As shown in Figure 6, energetic penalties for individual substitutions ranged from 0.6 to 4.7 kcal/mol. First, we probed interactions between the N6 amine and N1 of adenine and Leu85 (Figure 3), the first residue in the conserved LDTG motif. Loss of the N6 amine from AMP reduced the free energy of binding to APS reductase by 1.8 kcal/mol. Replacing hydrogen atoms with methyl groups at the N6 position of adenine decreased binding affinity by 35-fold (2.1 kcal/mol) per substitution. Inverting the hydrogen bond donor and acceptor, as in inosine-5′-monophosphate, was also disfavored (4.7 kcal/mol), presumably due to electrostatic repulsion between the O6-keto and the Leu85 carbonyl, and the N1 by the Leu85 amine. Likewise, introduction of an N1 amine markedly reduced the affinity of this analogue for APS reductase (4.7 kcal/mol). In subsequent experiments, we determined the binding potency of AMP analogues with


Figure 9. Pharmacophore model of substrate, APS. Chemical structure of APS highlighting key hydrogen bond accepting (HBA) and donating (HBD) interactions, ionic interactions, and van der Waals interactions based on functional data obtained in the present study.

substitutions at the 2-, 7-, and 8-positions of the purine ring. Methylation at N2 had a detrimental effect on binding (3.4 kcal/mol), likely due to steric clashes with the surrounding adenine-binding pocket (Figure 3). The structure of APS reductase bound to APS shows that C8–H group is directed toward the 5′-phosphosulfate moiety (Figure 3). Not surprisingly then, amine substitution at this position decreased the free energy of binding by 3.7 kcal/mol. No contacts are formed between N7 and APS reductase (Figure 3). Consistent with this observation, replacing N7 with a carbon atom had a relatively minor effect on binding affinity (0.6 kcal/mol). Finally, we investigated the influence of modification at the 2′- and 3′-hydroxyl groups of the ribose sugar. 2′-deoxy and methoxy group substitutions reduced the free energy of binding by a respective 4.0 and 3.6 kcal/mol, whereas 3′-deoxy substitution had only a modest effect on binding affinity (0.9 kcal/mol). This indicates that hydrogen bonds between the 2′-hydroxy group and Ser60 and Gly161 residues (Figure 3) play a vital role in substrate recognition.

2.5. pH Dependence of Ligand Binding. The pH dependence for ligand binding provides information about the relative affinities of the different nucleotide ionization states and thus provides information about the active site environment. Initially, we investigated the pH dependence for APS binding. However, the substantial increase in reaction rate at higher pH precludes measurement by conventional kinetic methods (data not shown). As an alternative, we determined the affinities of APS reductase for the substrate analogue, ADP, and product, AMP, as a function of pH to investigate whether ionizations at α- and β-positions are important for binding affinity (Figure 7). The pH dependence for ADP binding is best fit by a pK_a of 6.4 ± 0.2, which could reflect ionizations of the free enzyme and ligand (Figure 7A). The most likely candidate for this ionization is the ligand, as the second pK_a values of phosphate esters fall in this region.[35] If this were true, the pH profile would be expected to shift to lower pH for an ADP analogue with lower pK_a values. To test this, we determined the pH dependence for ADPβS, which differs in its respective pK_a value by approximately one pH unit.[27] The pH dependence for ADPβS binding is best fit by a pK_a of 5.8 ± 0.2 (Figure S3A, Supporting Information). The dependence of the pK_a upon the identity of the ligand suggests that deprotonation of the ligand is responsible for the increase in binding at higher pH.

The pH dependence for AMP binding is best fit by a pK_a of 8.1 ± 0.1 (Figure 7B), which could reflect ionizations of the free enzyme and ligand, as described above. The simplest model to explain the weaker binding of AMP below pH 8 is that the dianion binds more tightly than the monoanion. However, the apparent pK_a for AMP differs from the expected pK_a of 6.8 by more than one unit. The discrepancy between the experimental data and the simplest model is most likely due to concurrent ionization of the enzyme that affects ligand binding, leading to shift in the apparent pK_a of AMP. One model that could account for this upward deviation is that an enzymatic group with a pK_a of ∼6 contributes slightly (∼5-fold) to AMP binding when protonated. The most likely residue to exert such an effect on ligand binding is His259, which interacts with the 5′-phosphate of PAP in the structure of *S. cerevisiae* PAPS reductase.[14] Because a stimulatory effect is not observed for ADP binding, the C-terminal segment containing His259, and possibly the Arg-loop, may adopt different conformations depending on whether ADP or AMP is bound at the active site. To fur-

ther confirm that the apparent pK_a measured for AMP depends upon the identity of the ligand, we measured the pH dependence for AMPS binding (Figure S3B, Supporting Information). The resulting data are best fit by a pK_a of 7.7 ± 0.1. The downward shift in apparent pK_a suggests that deprotonation of the ligand is responsible for the increase in binding at higher pH.

The observed pH dependence for ADP and AMP binding indicates that the dianion binds more tightly to APS reductase than the monoanion. These data seemingly contradict our earlier comparison between ADP and ADPβF, whose net charges differ by one unit but bind to APS reductase with similar affinity (Table 2 and Figure 5). Indeed, fluorine modification is often used to determine whether binding of mono- or dianionic phosphate is favored.[36] However, hydroxyl and fluorine groups are distinguished by unique chemical properties. For example, the high electron density of fluorine gives rise to the ability to act as an acceptor in hydrogen bonds.[37] By contrast, the hydroxyl group is a strong dipole, with spatially separated partial positive and negative charges that can donate as well as accept hydrogen bonds (Figure 5). Hence, the weaker binding observed for the monoanion may not reflect a loss of charge–charge interactions but rather an energetic penalty that results from unfavorable charge–dipole interactions with the hydroxyl group.

2.6. Effect of Mg^{2+} on Ligand Affinity. In the absence of metal ions, APS binds ∼20-times tighter to APS reductase, compared to ADP and AMP. However, the cellular concentrations of these nucleotides are higher than APS[38] and thus raise an important question: How does APS compete against binding of ADP or AMP to the active site of APS reductase in the cell? For the majority of biochemical reactions using ATP and related nucleotides, the active species is the Mg^{2+} complex rather than the free nucleotide.[39] To gain insight into ligand discrimination by APS reductase in vivo, we measured the K_d values for APS, ADP, and AMP in the presence of Mg^{2+}. These studies show that the K_d value of APS was independent of Mg^{2+} concentration (data not shown). This observation is consistent with weak formation constants of APS with Mg^{2+}[40] and the general observation that other sulfonucleotide binding enzymes, such sulfokinases and sulfotransferases, also do not require Mg^{2+} as a cofactor.[11] However, Mg•ADP and Mg•AMP complexes bind approximately 5–6 times weaker to APS reductase as compared to the free nucleotide (Table S2, Supporting Information). The observed reduction in binding energy is most likely due to repelling interactions with multiple positively charged amino acids in the enzyme active site, such as Lys144, Arg242, and Arg245 (Figure 3). Together, these findings indicate that APS reductase discriminates against noncognate adenosine nucleotides through favorable interactions with the sulfate moiety of APS and by disfavoring the binding of Mg^{2+}-nucleotide complexes.

2.7. Implications for Rational Inhibitor Design. Given that APS reductase is essential for mycobacterial survival during persistent infection,[9] small-molecule inhibitors of APS reductase might be a source for new drugs to treat latent tuberculosis infection. The increasing number of antibiotic-resistant strains suggests that the availability of such compounds could play an important role in treating the disease and minimizing the negative impact on human health. By defining chemical groups that are essential for molecular recognition, the work described here sets the stage for the development of such drugs. Figure 8 summarizes the net-

work of interactions predicted to occur between APS reductase active site residues and substrate, APS. The structural model was constructed by homology to *S. cerevisiae* PAPS reductase[14] and systematically tested in the present study from the perspective of the ligand. The total binding energy of APS resulting from these collective interactions is 9.3 kcal/mol, and our data indicate several features that are essential for optimized substrate and inhibitor binding. The hydrophobic adenine-binding pocket, pyrimidine ring, 2′-hydroxyl, and the α-position are the main determinants for strong target affinity (Figure 9). The significant losses of binding affinity that are found to result from apparently minor structural modifications of ligands at these key positions have encouraging implications for inhibitor design and suggests that, in some cases, the potency of a weak inhibitor might be greatly enhanced by one or two simple modifications. Our studies also suggest that small molecules that target dynamic elements within the active site, particularly Arg171, Cys256, and His259, may lead to inhibitors with improved binding affinity. Alternatively, molecules that trap an inactive, "open" conformational state of APS reductase may also represent new opportunities for inhibitor design.[16]

3. Experimental Procedures

3.1. Materials. Adenosine, 2-aminoadenosine, 3′-deoxyadenosine, 2′-deoxyadenosine, 1-methyladenosine, and inosine-5′-*O*-monophosphate were purchased from Sigma. 5′-Phosphoribose, 3′-phosphoadenosine, 3′5′-diphosphoadenosine, adenine, and ribose were also purchased from Sigma. 7-Deazaadenosine-5′-*O*-monophosphate and purine riboside-5′-*O*-monophosphate were from Biology Life Science Institute. Purchased nucleosides and other analogues were of the highest purity available (≥95%) and were used without further purification. Additional reagents and solvents were purchased from Sigma or other commercial sources and were used without further purification.

3.2. General Synthetic Methods. Reactions that were moisture sensitive or using anhydrous solvents were performed under a nitrogen or argon atmosphere. Analytical thin layer chromatography (TLC) was performed on precoated silica plates obtained from Analtech. Visualization was accomplished with UV light or by staining with ethanolic H_2SO_4 or ceric ammonium molybdate. Nucleosides were purified by flash chromatography using Merck silica gel (60–200 mesh).

3.3. Preparation of Nucleoside and Nucleotide Analogues. N^6, N^6-Dimethyl-5′-adenosine was prepared from inosine by the procedure described by Veliz and Beal[41] and purified by flash chromatography developed in 60:40 ethyl acetate:hexanes. N^6-Methyl-5′-adenosine was prepared via reaction of 6-bromoinosine with methylamine as previously described.[42] 8-Aminoadenosine was prepared by selective bromination of adenosine at the C8 position, exchange of bromine for azide, followed by reductive hydrogenation to afford the amine, as previously described.[43] 2′-Methoxyadenosine was prepared from adenosine by reaction with methyl iodide under alkaline conditions as previously described.[44] Adenosine-5′-*O*-α,β,-imidodiphosphate (AMPNP) was synthesized by reaction of 5′-tosyladenosine[45] with imidodiphosphate salt.[45,46] Adenosine-5′-*O*-α,β-difluoromethylenediphosphate (AMPCF$_2$P) was prepared by coupling 5′-tosyladenosine to difluoro substituted methylenediphosphonic acid, as previously reported.[45,47] Adenosine-5′-*O*-thiophosphosulfate (APSαS) was synthesized by reacting pyridine-*N*-sulfonic acid with adenosine-5′-*O*-thiophosphate (AMPS), as previously described.[48] Structures and purity (≥95%) were confirmed by ^{1}H, ^{31}P NMR, and HPLC analysis (data not shown).

3.4. Nucleoside Phosphorylation. Nucleotide analogues (2′-deoxy-5′-phosphoadenosine, 2′-methoxy-5′phosphoadenosine,

N^6, N^6-dimethyl-5′-phosphoadenosine, N^6-methyl-5′-phosphoadenosine, 8-amino-5′-phosphoadenosine, 1-methyl-5′-phosphoadenosine, and 2-amino-5′-phosphoadenosine) were synthesized by chemical phosphorylation of the corresponding adenosine analogue, followed by purification via reversed phase HPLC. Nucleosides were phosphorylated by reaction of nucleoside with $POCl_3$ as described.[49] The nucleoside (0.15 mmol) was suspended in triethylphosphate at 0 °C (0.65 mL). Water (1 equiv) was added to the reaction. Subsequently, $POCl_3$ (3–5 equiv, 42–70 μL) was added over a period of 30 min with constant stirring. The suspension was kept stirring for an additional 1.5 h, when the white suspension became a clear solution. Water (1 mL) was added to hydrolyze the phosphoryl chloride and terminate the reaction. The pH was neutralized to ∼7 by dropwise addition of 1 M NH_4OH. The reaction was passed over a 2 g C18 SPE column (Fisher) that was conditioned in acetonitrile (6 mL) followed by H_2O (6 mL). The nucleotide was eluted from the C18 SPE column with H_2O. Nucleotides were purified by reversed phase HPLC employing isocratic separation in 20 mM ammonium acetate, pH 7, on a semipreparative (10 × 25 cm) C18 column, and the solvent was removed from the solution by repeated lyophilization. The physical and spectral data for these analogues (confirmed by ^{1}H, ^{13}C, and ^{31}P NMR and mass spectrometry) were consistent with those previously reported for these compounds.[49–51] The purity (≥95%) was confirmed by HPLC analysis using the conditions described above. The retention time of each nucleotide analogue (N^6, N^6-dimethyl-5′-phosphoadenosine, N^6-methyl-5′-phosphoadenosine, 2′-methoxy-5′phosphoadenosine, 2′-deoxy-5′-phosphoadenosine, 8-amino-5′-phosphoadenosine, 1-methyl-5′-phosphoadenosine, and 2-amino-5′-phosphoadenosine) was 19.7, 19.6, 8.5, 6.1, 4.4, 4, and 3.5 min, respectively. The concentrations of nucleotide analogues was determined by absorbance at 260 nm, assuming $\varepsilon_{260} = 15400$ M^{-1} cm^{-1}.[52]

3.5. Enzyme Purification. Purification of APS reductase was carried out as previously described.[10]

3.6. General Kinetic Methods. ^{35}S-labeled APS was synthesized and purified as previously described[10] with the inclusion of an additional anion exchange purification step on a 5 mL FFQ column (GE Healthcare) eluting with a linear gradient of ammonium bicarbonate, pH 8.0. The reduction of APS to sulfite and AMP was measured in a ^{35}S-based assay as previously described.[53] Reactions were quenched by the addition of charcoal solution (2% w/v) containing Na_2SO_3 (20 mM). The suspension was vortexed, clarified by centrifugation, and an aliquot of the supernatant containing the radiolabeled sulfite product was counted in scintillation fluid. APS reductase activity was measured in single turnover reactions, with trace amounts of ^{35}S-APS (∼1 nM) and excess protein. These reactions can typically be followed to ≥90% completion (Figure S4A, Supporting Information), and the reaction time courses fit well to eq 1, in which Frac *P* is the fraction product, *k* is the observed rate constant, and *t* is time:

$$\mathrm{Frac}P = 1 - \exp^{-k_{\mathrm{obs}}t} \tag{1}$$

Unless otherwise specified, the standard reactions conditions were 30 °C with 100 mM bis-tris propane at pH 7.5, DTT (5 mM), and thioredoxin (10 μM). Kinetic data were measured in at least two independent experiments, and the standard error was typically less than 15%.

The affinity of APS reductase (*E*) for APS was determined from the dependence of the observed rate constant for *S*-sulfocysteine formation on protein concentration according to eq 2:

$$k_{\mathrm{obs}} = k_{\mathrm{max}} \times \left(\frac{[E]}{K_{1/2} + [E]} \right) \tag{2}$$

In this equation, k_{obs} is the observed rate constant at a particular protein concentration, k_{max} is the maximal rate constant with

saturating protein, and $K_{1/2}$ is the protein concentration that provides half the maximal rate. To ensure that the chemical step was rate-determining, reactions were performed in NaMes (10 mM) at pH 5.5, and control experiments demonstrate that the enzyme is stable under these assay conditions (data not shown). Because the chemical step is rate-determining for *S*-sulfocysteine formation ($k_{st} < k_{max}$ is equal to the rate constant for the reaction of the *E*•APS complex, and $K_{1/2}$ is equal to the dissociation constant (K_d) of APS for APS reductase. The concentration of active protein was determined by direct titration with a high concentration of APS (i.e., [APS] $\gg K_d$). In theory, the binding affinity of APS could increase at physiological pH. However, several lines of evidence argue against this possibility. First, the pK_a of the β-sulfate moiety is less than 2 and thus, at pH 5.5, the sulfonucleotide is completely ionized. Second, the pH dependence of ADP binding (see below) reflects the pK_a of this nucleotide in solution. Finally, the K_d measured at pH 5.5 is in line with the apparent K_m value measured at pH 8.0.[22]

The affinity of various ligands for APS reductase was determined by inhibition methods. The observed rate constant of the reaction: $E + {}^{35}\text{S-APS} \rightarrow \text{products}$ (k_{obs}) was determined at varying inhibitor (I) concentrations (Figure S4B, Supporting Information), and the [I]-dependence was fit to a simple model for competitive inhibition (eq 3). In eq 3, k_o is the rate of the reaction in the absence of analogue, and K_i is the inhibition constant of the analogue. With subsaturating APS reductase, K_i is equal to the equilibrium dissociation constant (K_d) of the ligand.

$$k_{obs} = k_o \times \left(\frac{K_i}{[I] + K_i} \right) \quad (3)$$

3.7. pH Dependence of Inhibitor Binding. Values of K_i were determined by inhibition of APS reduction (pH 6–9.5) with $[{}^{35}\text{S-APS}] \ll K_{1/2}$, such that K_i is expected to be the K_d. The following buffers were used for the indicated pH ranges: NaMES (6.0–7.0), Bis-Tris (6.5–7.5), Tris (7.5–9.0), and CAPS (9.0–9.5). Reactions were typically carried out with 100 mM buffer, and the standard assays and conditions described above were used to monitor k_{cat}/K_m for reduction of ${}^{35}\text{S-APS}$ in the presence and absence of inhibitor. The rate constants at each pH value for multiple reactions were averaged, and the standard deviations were ≤15% of the average. pK_a values were determined using eq 4, derived from a model where the binding of the ligand depends on a single ionizable group.

$$K_{d, app} = K_d^{HA} \times \frac{K_a}{K_a + [\text{H}^+]} + K_d^{A^-} \times \frac{[\text{H}^+]}{K_a + [\text{H}^+]} \quad (4)$$

3.8. Energetic Contribution of Ligand Substituents to Binding. The energetic contributions of individual ligand substituents to APS reductase binding were expressed as $\Delta\Delta G = -RT \ln(K_d 1/K_d 2)$ in which R is the gas constant, T is the temperature (303 K), and K_d is the equilibrium dissociation constant. A negative value of $\Delta\Delta G$ indicates that a given substituent contributes to ligand binding by APS reductase.

3.9. Electrostatic Surface Potentials. The electrostatic surface potential was calculated using PM3 semiempirical molecular orbital calculations implemented in SPARTAN software (Wave function, Inc.) for the fully optimized structure.

Supporting Information Available: Ligand dissociation constants for nitrogen-containing ligands at pH 7.5 and pH 9.0 with APS reductase. Ligand dissociation constants for AMP and ADP with APS reductase in the presence and absence of MgCl2. Structure-based sequence alignment of APS reductases from *Pseudomonas aeruginosa*, *Mycobacterium tuberculosis*, and *Saccharomyces cerevisiae*. The apparent affinity, $K_{1/2}$, of APS reductase in single turnover experiment. pH dependence for ADPβS (A) and AMPS (B) binding. The radioactive assay for APS reductase. This material is available free of charge via the Internet at http://pubs.acs.org.

References

(1) Schelle, M. W.; Bertozzi, C. R. Sulfate metabolism in mycobacteria. *ChemBioChem* **2006**, *7*, 1516–1524.
(2) Mitchell, S. Biology of sulfur. In *Biological Interactions of Sulfur Compounds*; Mitchell, S., Ed.; CRC Press: New York, 1996; Vol. 1, pp 20–41.
(3) Kredich, N. M. Biosynthesis of cysteine. In *Escherichia coli and Salmonella: Cellular and Molecular Biology*, 2nd ed.; Niedhardt, F. C., Curtiss, R., Eds.; ASM Press: Washigton, D. C., 1996; Vol. 1, pp 514–527.
(4) Giles, N. M.; Watts, A. B.; Giles, G. I.; Fry, F. H.; Littlechild, J. A.; Jacob, C. Metal and redox modulation of cysteine protein function. *Chem. Biol.* **2003**, *10*, 677–693.
(5) Williams, S. J.; Senaratne, R. H.; Mougous, J. D.; Riley, L. W.; Bertozzi, C. R. 5′-Adenosine phosphosulfate lies at a metabolic branch point in mycobacteria. *J. Biol. Chem.* **2002**, *277*, 32606–32615.
(6) Kopriva, S.; Buchert, T.; Fritz, G.; Suter, M.; Benda, R.; Schunemann, V.; Koprivova, A.; Schurmann, P.; Trautwein, A. X.; Kroneck, P. M.; Brunold, C. The presence of an iron-sulfur cluster in adenosine 5′-phosphosulfate reductase separates organisms utilizing adenosine 5′-phosphosulfate and phosphoadenosine 5′-phosphosulfate for sulfate assimilation. *J. Biol. Chem.* **2002**, *277*, 21786–21791.
(7) Bhave, D. P.; Muse, W. B.III; Carroll, K. S. Drug targets in mycobacterial sulfur metabolism. *Infect. Disord. Drug Targets* **2007**, *7*, 140–158.
(8) Mdluli, K.; Spigelman, M. Novel targets for tuberculosis drug discovery. *Curr. Opin. Pharmacol.* **2006**, *6*, 459–467.
(9) Senaratne, R. H.; De Silva, A. D.; Williams, S. J.; Mougous, J. D.; Reader, J. R.; Zhang, T.; Chan, S.; Sidders, B.; Lee, D. H.; Chan, J.; Bertozzi, C. R.; Riley, L. W. 5′-Adenosinephosphosulfate reductase (CysH) protects *Mycobacterium tuberculosis* against free radicals during chronic infection phase in mice. *Mol. Microbiol.* **2006**, *59*, 1744–1753.
(10) Carroll, K. S.; Gao, H.; Chen, H.; Stout, C. D.; Leary, J. A.; Bertozzi, C. R. A conserved mechanism for sulfonucleotide reduction. *PLoS Biol.* **2005**, *3*, e250.
(11) Carroll, K. S.; Gao, H.; Chen, H.; Leary, J. A.; Bertozzi, C. R. Investigation of the iron−sulfur cluster in *Mycobacterium tuberculosis* APS reductase: implications for substrate binding and catalysis. *Biochemistry* **2005**, *44*, 14647–14657.
(12) Chartron, J.; Carroll, K. S.; Shiau, C.; Gao, H.; Leary, J. A.; Bertozzi, C. R.; Stout, C. D. Substrate recognition, protein dynamics, and iron−sulfur cluster in *Pseudomonas aeruginosa* adenosine 5′-phosphosulfate reductase. *J. Mol. Biol.* **2006**, *364*, 152–169.
(13) Chapman, E.; Best, M. D.; Hanson, S. R.; Wong, C. H. Sulfotransferases: structure, mechanism, biological activity, inhibition, and synthetic utility. *Angew. Chem., Int. Ed.* **2004**, *43*, 3526–3548.
(14) Yu, Z.; Lemongello, D.; Segel, I. H.; Fisher, A. J. Crystal structure of *Saccharomyces cerevisiae* 3′-phosphoadenosine-5′-phosphosulfate reductase complexed with adenosine 3′,5′-bisphosphate. *Biochemistry* **2008**, *47*, 12777–12786.
(15) Young, D. B.; Gideon, H. P.; Wilkinson, R. J. Eliminating latent tuberculosis. *Trends Microbiol.* **2009**, *17*, 183–188.
(16) Lee, G. M.; Craik, C. S. Trapping moving targets with small molecules. *Science* **2009**, *324*, 213–215.
(17) Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations. *Nat. Chem. Biol.* **2006**, *2*, 358–364.
(18) Hugonnet, J. E.; Tremblay, L. W.; Boshoff, H. I.; Barry, C. E.III; Blanchard, J. S. Meropenem-clavulanate is effective against extensively drug-resistant *Mycobacterium tuberculosis*. *Science* **2009**, *323*, 1215–1218.
(19) Palomino, J. C.; Ramos, D. F.; da Silva, P. A. New anti-tuberculosis drugs: strategies, sources and new molecules. *Curr. Med. Chem.* **2009**, *16*, 1898–1904.
(20) Nguyen, L.; Pieters, J. Mycobacterial Subversion of Chemotherapeutic Reagents and Host Defense Tactics: Challenges in Tuberculosis Drug Development. *Annu. Rev. Pharmacol. Toxicol.* **2009**, *49*, 427–453.
(21) Cosconati, S.; Hong, J. A.; Novellino, E.; Carroll, K. S.; Goodsell, D. S.; Olson, A. J. Structure-based virtual screening and biological evaluation of *Mycobacterium tuberculosis* adenosine 5′-phosphosulfate reductase inhibitors. *J. Med. Chem.* **2008**, *51*, 6627–6630.

(22) Sun, M.; Leyh, T. S. Channeling in sulfate activating complexes. *Biochemistry* **2006**, *45*, 11304–11311.

(23) Dzingeleski, G. D.; Wolfenden, R. Hypersensitivity of an enzyme reaction to solvent water. *Biochemistry* **1993**, *32*, 9143–9147.

(24) Carlow, D.; Wolfenden, R. Substrate connectivity effects in the transition state for cytidine deaminase. *Biochemistry* **1998**, *37*, 11873–11878.

(25) Nikolic-Hughes, I.; Rees, D. C.; Herschlag, D. Do electrostatic interactions with positively charged active site groups tighten the transition state for enzymatic phosphoryl transfer? *J. Am. Chem. Soc.* **2004**, *126*, 11814–11819.

(26) *CRC Handbook of Chemistry and Physics.* 75th ed.; CRC Press: Boca Raton, FL, 1994−1995; pp 9−12.

(27) Jaffe, E. K.; Cohn, M. ^{31}P nuclear magnetic resonance spectra of the thiophosphate analogues of adenine nucleotides; effects of pH and Mg^{2+} binding. *Biochemistry* **1978**, *17*, 652–657.

(28) Frey, P. A.; Sammons, R. D. Bond order and charge localization in nucleoside phosphorothioates. *Science* **1985**, *228*, 541–545.

(29) Satishchandran, C.; Myers, C. B.; Markham, G. D. Adenosine-5′-*O*-(2-fluorodiphosphate) (ADP-β-F), an analog of adenosine-5′-phosphosulfate. *Bioorganic Chem.* **1992**, *20*, 107–114.

(30) Gregoret, L. M.; Rader, S. D.; Fletterick, R. J.; Cohen, F. E. Hydrogen bonds involving sulfur atoms in proteins. *Proteins* **1991**, *9*, 99–107.

(31) Yount, R. G.; Babcock, D.; Ballantyne, W.; Ojala, D. Adenylyl imidodiphosphate, an adenosine triphosphate analog containing a P−N−P linkage. *Biochemistry* **1971**, *10*, 2484–2489.

(32) Larsen, M.; Willett, R.; Yount, R. G. Imidodiphosphate and pyrophosphate: possible biological significance of similar structures. *Science* **1969**, *166*, 1510–1511.

(33) Reynolds, M. A.; Gerlt, J. A.; Demou, P. C.; Oppenheimer, N. J.; Kenyon, G. L. N-15 and O-17 NMR-studies of the proton binding-sites in imidodiphosphate, tetraethyl imidodiphosphate, and adenylyl imidodiphosphate. *J. Am. Chem. Soc.* **1983**, *105*, 6475–6481.

(34) Savage, H.; Montoya, G.; Svensson, C.; Schwenn, J. D.; Sinning, I. Crystal structure of phosphoadenylyl sulphate (PAPS) reductase: a new family of adenine nucleotide alpha hydrolases. *Structure* **1997**, *5*, 895–906.

(35) Cullis, P. M.; Maxwell, A.; Weiner, D. P. Energy coupling in DNA gyrase: a thermodynamic limit to the extent of DNA supercoiling. *Biochemistry* **1992**, *31*, 9642–9646.

(36) Rye, C. S.; Baell, J. B. Phosphate isosteres in medicinal chemistry. *Curr. Med. Chem.* **2005**, *12*, 3127–3141.

(37) O'Hagan, D. Understanding organofluorine chemistry. An introduction to the C−F bond. *Chem. Soc. Rev.* **2008**, *37*, 308–319.

(38) Harris, D. A. Cell chemistry and physiology: part II. In *Principles of Medical Biology*; Bittar, E. E.; Bittar, N., Eds.; Elsevier: New York, 1996; Vol. 4, p 27.

(39) Storer, A. C.; Cornish-Bowden, A. Concentration of MgATP^{2-} and other ions in solution. Calculation of the true concentrations of species present in mixtures of associating ions. *Biochem. J.* **1976**, *159*, 1–5.

(40) Yount, R. G.; Simchuck, S.; Yu, I.; Kottke, M. Adenosine-5′-sulfatopyrophosphate, an analogue of adenosine triphosphate. I. Preparation, properties, and mode of cleavage by snake venoms. *Arch. Biochem. Biophys.* **1966**, *113*, 288–295.

(41) Veliz, E. A.; Beal, P. A. C6 substitution of inosine using hexamethylphosphorous triamide in conjunction with carbon tetrahalide or *N*-halosuccinimide. *Tetrahedron Lett.* **2000**, *41*, 1695–1697.

(42) Veliz, E. A.; Beal, P. A. 6-Bromopurine nucleosides as reagents for nucleoside analogue synthesis. *J. Org. Chem.* **2001**, *66*, 8592–8598.

(43) Townsend, L. B.; Tipson, R. S. *Nucleic Acid Chemistry: Improved and New Synthetic Procedures, Methods, and Techniques.* Wiley: New York, 1978; Vol. II.

(44) Yano, J.; Kan, L. S.; Ts'o, P. O. P. A simple method for the preparation of adenosine with methyl iodide in anhydrous alkaline medium. *Biochim. Biophys. Acta* **1980**, *629*, 178–183.

(45) Davisson, V. J.; Davis, D. R.; Dixit, V. M.; Poulter, C. D. Synthesis of nucleotide 5′-diphosphates from 5′-*O*-tosyl nucleosides. *J. Org. Chem.* **1987**, *52*, 1794–1801.

(46) Ma, Q.; Babbitt, P. C.; Kenyon, G. L. Adenosine 5′-[α,β-imido]-triphosphate, a substrate for T7 RNA-polymerase and rabbit muscle creatine-kinase. *J. Am. Chem. Soc.* **1988**, *110*, 4060–4061.

(47) Mohamady, S.; Jakeman, D. L. An improved method for the synthesis of nucleoside triphosphate analogues. *J. Org. Chem.* **2005**, *70*, 10588–10591.

(48) Zhang, H. P.; Leyh, T. S. alpha-Thio-APS: A stereomechanistic probe of activated sulfate synthesis. *J. Am. Chem. Soc.* **1999**, *121*, 8692–8697.

(49) Yoshikawa, M.; Kato, T.; Takenishi, T. A novel method for phosphorylation of nucleosides to 5′-nucleotides. *Tetrahedron Lett.* **1967**, *50*, 5065–5068.

(50) Burgess, K.; Cook, D. Syntheses of nucleoside triphosphates. *Chem. Rev.* **2000**, *100*, 2047–2059.

(51) Freist, W.; Cramer, F. Synthesis of AMP and ATP analogues. In *In Nucleic Acid Chemistry, Part 2*; Townsend, L. W., Tipson, R. S., Eds.; John Wiley & Sons: New York, 1978; pp 827−841.

(52) Dawson, R. M. C.; Elliott, D. C.; Elliott, W. H.; Jones, K. M. *Data for Biochemical Research.* 3rd ed.; Oxford University Press: Oxford, 1989.

(53) Gao, H.; Leary, J.; Carroll, K. S.; Bertozzi, C. R.; Chen, H. Y. Noncovalent complexes of APS reductase from M-tuberculosis: Delineating a mechanistic model using ESI-FTICR MS. *J. Am. Soc. Mass Spectrom.* **2007**, *18*, 167–178.

(54) Chargaff, E.; Davidson, J. N. *The Nucleic Acids I*; Academic Press: New York, 1955.

(55) Kumler, W. D.; Eiler, J. J. The acid strength of mono and diesters of phosphoric acid. The *n*-alkyl esters from methyl to butyl, the esters of biological importance, and the natural guanidine phosphoric acids. *J. Am. Chem. Soc.* **1943**, *65*, 2355–2361.

(56) Isbell, H. S. *Carbohydrate in Solution*; American Chemical Society: Wachington, DC, 1973.

(57) Chang, R. Acids and bases. In *General Chemistry*, 8th ed.; McGraw-Hill Inc.: New York, 2005.

(58) Hirota, K.; Inoue, Y.; Chujo, R. Effect of the base stacking association on the phosphate ionization of 2'-deoxyguanosine 5′-monophosphate. *Bull. Chem. Soc. Jpn.* **1984**, *57*, 247–250.

(59) Falany, C. N. Enzymology of human cytosolic sulfotransferases. *FASEB J.* **1997**, *11*, 206–216.

(60) Jaffe, E. K.; Cohn, M. ^{31}P nuclear magnetic resonance spectra of the thiophosphate analogues of adenine nucleotides; effects of pH and Mg^{2+} binding. *Biochemistry* **1978**, *17*, 652–657.

(61) Cullis, P. M.; Maxwell, A.; Weiner, D. P. Energy coupling in DNA gyrase: a thermodynamic limit to the extent of DNA supercoiling. *Biochemistry* **1992**, *31*, 9642–9646.

(62) Vogel, H. J.; Bridger, W. A. Phosphorus-31 nuclear magnetic resonance studies of the methylene and fluoro analogues of adenine nucleotides. Effects of pH and magnesium ion binding. *Biochemistry* **1982**, *21*, 394–401.

(63) Rye, C. S.; Baell, J. B. Phosphate isosteres in medicinal chemistry. *Curr. Med. Chem.* **2005**, *12*, 3127–3141.

(64) Chanley, J. D.; Feageson, E. A study of hydrolysis of phosphoramides 0.2. Solvolysis of phosphoramidic acid and comparison with phosphate esters. *J. Am. Chem. Soc.* **1963**, *85*, 1181–1190.

(65) Singer, B. Nucleosides, nucleotides, and nucleic acids. In *Practical Handbook of Biochemistry and Molecular Biology*, 2nd ed.; Fasman, G. D., Ed.; CRC Press: Cleveland, 1989; Vol. 1, pp 392−393.